We are live on ! Find out more
IMMX icon

Immix Biopharma
IMMX

16 hedge funds and large institutions have $1.39M invested in Immix Biopharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.31% less ownership

Funds ownership: 4.37% → 2.06% (-2.3%)

11% less funds holding

Funds holding: 18 → 16 (-2)

21% less capital invested

Capital invested by funds: $1.75M → $1.39M (-$362K)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$29.8K
2
TAM
Tocqueville Asset Management
New York
+$28.1K
3
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$14.1K
4
BlackRock
BlackRock
New York
+$5.49K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2K

Top Sellers

Rank Fund Capital Flow
1
LCM
Lynwood Capital Management
Ontario, Canada
-$539K
2
UB
UMB Bank
Missouri
-$195K
3
Renaissance Technologies
Renaissance Technologies
New York
-$29K
4
PA
Parallel Advisors
California
-$7.77K
5
TRCT
Tower Research Capital (TRC)
New York
-$323
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$363K +$2K +853 +0.8%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$250K +$29.8K +12,696 +21%
Koshinski Asset Management
3
Koshinski Asset Management
Illinois
$174K – – –
State Street
4
State Street
Massachusetts
$147K – – –
Commonwealth Equity Services
5
Commonwealth Equity Services
Massachusetts
$99K +$14.1K +6,030 +26%
IW
6
Imprint Wealth
South Carolina
$78.9K +$1.88K +803 +4%
MAWA
7
Moss Adams Wealth Advisors
Washington
$68.4K – – –
BlackRock
8
BlackRock
New York
$61.5K +$5.49K +2,343 +15%
ICG
9
InterOcean Capital Group
Tennessee
$54.4K – – –
TAM
10
Tocqueville Asset Management
New York
$41K +$28.1K +12,000 New
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$40.7K +$9 +4 +0%
TIM
12
Tortoise Investment Management
New York
$4.45K +$703 +300 +30%
Morgan Stanley
13
Morgan Stanley
New York
$1.37K +$938 +400 New
Osaic Holdings
14
Osaic Holdings
Arizona
$1.2K – – –
Wells Fargo
15
Wells Fargo
California
$195 +$35 +15 +36%
JP Morgan Chase
16
JP Morgan Chase
New York
$24 +$16 +7 New
LCM
17
Lynwood Capital Management
Ontario, Canada
– -$539K -200,250 Closed
UB
18
UMB Bank
Missouri
– -$195K -72,639 Closed
Renaissance Technologies
19
Renaissance Technologies
New York
– -$29K -10,600 Closed
PA
20
Parallel Advisors
California
– -$7.77K -2,890 Closed
TRCT
21
Tower Research Capital (TRC)
New York
– -$323 -120 Closed

IMMX Hedge Fund Activity: Q3 2023 in Review

16 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2023, worth a combined $1.39M — down 21% from $1.75M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IMMX and 3 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 8 added.

The largest buyer was Geode Capital Management, adding an estimated $29.8K. The largest seller was Lynwood Capital Management, exiting entirely with an estimated $539K sold.

  • 16 institutional investors held Immix Biopharma (IMMX) as of Q3 2023, down from 18 in Q2 2023.
  • Funds reported $1.39M of Immix Biopharma stock for Q3 2023, down 21% quarter-over-quarter.
  • 3 funds opened new Immix Biopharma positions in Q3 2023 and 5 closed out, a net change of -2 holders.
  • The largest Immix Biopharma buyer in Q3 2023 was Geode Capital Management, an estimated $29.8K added.
  • The largest Immix Biopharma seller in Q3 2023 was Lynwood Capital Management, an estimated $539K sold.

Based on aggregated 13F filings for Q3 2023.